Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.97 |
| ▸ | LHCGR | P22888 | 1/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.74 |
| ▸ | RAB9A | P51151 | 1/20 | 0.74 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.73 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.73 |
| ▸ | FAAH2 | Q6GMR7 | 1/20 | 0.73 |
| ▸ | MGLL | Q99685 | 1/20 | 0.73 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29393643 | 0.99 | FAAH (1.00) | FAAHLHCGRALDH1A1RAB9ATRPA1 | |
| SCHEMBL530169 | 0.99 | FAAH (1.00) | FAAHLHCGRALDH1A1RAB9ATRPA1 | |
| SCHEMBL10089399 | 0.92 | FAAH (0.88) | FAAHLHCGRALDH1A1RAB9ATRPA1 | |
| SCHEMBL10089404 | 0.88 | FAAH (0.81) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL10089402 | 0.88 | FAAH (0.81) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL10089406 | 0.88 | FAAH (0.81) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL10089403 | 0.87 | FAAH (0.79) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL10089425 | 0.87 | FAAH (0.79) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL10089426 | 0.87 | FAAH (0.79) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL10089400 | 0.86 | FAAH (0.84) | FAAHTRPA1EPHX2FAAH2MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010283-A1 | MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-01-12 | — | — | US | disclosed |
| US-8003693-B2 | Modulation of anxiety through blockade of anandamide hydrolysis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003693-B2 | Modulation of anxiety through blockade of anandamide hydrolysis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-08-23 | — | — | US | disclosed |
| US-20090048337-A1 | Modulation of anxiety through blockade of anandamide hydrolysis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048337-A1 | Modulation of anxiety through blockade of anandamide hydrolysis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-02-19 | — | — | US | disclosed |
| US-7176201-B2 | Modulation of anxiety through blockade of anandamide hydrolysis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176201-B2 | Modulation of anxiety through blockade of anandamide hydrolysis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048337-A1 | Modulation of anxiety through blockade of anandamide hydrolysis | FAAH, FAAH2, CNR2 | FAAH 1/4885LHCGR 1634/4885ALDH1A1 681/4885 |
| US-20120010283-A1 | MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS | FAAH, FAAH2, CNR2 | FAAH 1/4885LHCGR 1617/4885ALDH1A1 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.